Wei Lun visiting professorial lecture: Nitric oxide in the regulation of vascular function: An historical overview

Journal of Cardiac Surgery

Volumn 17, Issue 4, 2001, Pages 301-306

  Ignarro, Louis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEME; NITRIC OXIDE;

BLOOD FLOW; BRONCHODILATATION; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; HOST RESISTANCE; HUMAN; NONHUMAN; SMOOTH MUSCLE; SMOOTH MUSCLE TONE; THROMBOCYTE AGGREGATION; VASODILATATION;

EID: 0036665223     PISSN: 08860440     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2001.tb01148.x     Document Type: Conference Paper

References (66)

1. Gruetter CA, Barry BK, McNamara DB, et al: Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Protein Phosphor Res 1979;5:211-224.
2. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376.
3. Mellion BT, Ignarro LJ, Ohlstein EH, et al: Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-955.
4. Mellion BT, Ignarro LJ, Myers CB, et al: Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 1983;23:653-664.
5. Gruetter CA, Barry BK, McNamara DB, et al: Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N′-nitrosonornicotine and nitric oxide. J Pharmacol Exp Ther 1980;214:9-15.
6. Gruetter DY, Gruetter CA, Barry BK, et al: Activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside, and nitrosoguanidine: Inhibition by calcium, lanthanum, and other cations, enhancement by thiols. Biochem Pharmacol 1980;29:2943-2950.
7. Gruetter CA, Gruetter DY, Lyon JE, et al: Relationship between cyclic guanosine 3′,5-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther 1981;219:181-186.
8. Ignarro LJ, Gruetter CA. Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: Possible involvement of S-nitrosothiols. Biochim Biophys Acta 1980;631:221-231.
9. Ignarro LJ, Edwards JC, Gruetter DY, et al: Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett 1980;110:275-278.
10. Ignarro LJ, Barry BK, Gruetter DY, et al: Guanylate cyclase activation of nitroprusside and nitrosoguanidine is related to formation of S-nitrosothiol intermediates. Biochem Biophys Res Commun 1980;94:93-100.
11. Ignarro LJ, Lippton H, Edwards JC, et al: Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
12. Ohlstein EH, Barry BK, Gruetter DY, et al: Methemoglobin blockade of coronary arterial soluble guanylate cyclase activation by nitroso compounds and its reversal with dithiothreitol. FEBS Lett 1979;102:316-320.
13. Katsuki S, Arnold W, Mittal C, et al: Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977;3:23-35.
14. Needleman P, Johnson EM: Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973;184:709-715.
15. Needleman P, Jakschik B, Johnson EM: Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973;187:324-331.
16. Axelsson KL, Anderson RGG, Wikberg JES: Vascular smooth muscle relaxation by nitro compounds: Reduced relaxation and cGMP elevation in tolerant vessels and reversal of tolerance by dithiothreitol. Acta Pharmacol Toxicol 1982;50:350-357.
17. Axelsson KL, Andersson RG: Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-79.
18. Horowitz JD, Antman EM, Lorell BH, et al: Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983;68:1247-1253.
19. Keith RA, Burkman AM, Sokoloski TD, et al: Vascular tolerance to nitroglycerin and cyclic GMP generation in rat aortic smooth muscle. J Pharmacol Exp Ther 1982;221:525-531.
20. May DC, Popma JJ, Black WH, et al: In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805-809.
21. Packer M, Lee WH, Kessler PD, et al: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
22. Winniford MD, Kennedy PL, Wells PJ, et al: Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation 1986;73:138-142.
23. DeRubertis FR, Craven PA: Calcium-independent modulation of cyclic GMP and activation of guanylate cyclase by nitrosamines. Science 1976;193:897-899.
24. Ignarro LJ, Kadowitz PJ: The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Ann Rev Pharmacol Toxicol 1985;25:171-191.
25. Gerzer R, Hofmann F, Schultz G: Purification of a soluble, sodium-nitroprusside-stimulated guanylate cyclase from bovine lung. Eur J Biochem 1981;116:479-486.
26. Gerzer R, Radany EW, Garbers DL: The separation of the heme and apoheme forms of soluble guanylate cyclase. Biochem Biophys Res Commun 1982;108:678-686.
27. Ignarro LJ, Wood KS, Wolin MS: Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci USA 1982;79:2870-2873.
28. Ignarro LJ, Degnan JN, Baricos WH, et al: Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 1982;718:49-59.
29. Ignarro LJ, Wood KS, Ballot B: Guanylate cyclase from bovine lung: Evidence that enzyme activation by phenylhydrazine is mediated by iron-phenyl hemoprotein complexes. J Biol Chem 1984;259:5923-5931.
30. Ignarro LJ, Ballot B, Wood KS: Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem 1984;259:6201-6207.
31. Ohlstein EH, Wood KS, Ignarro LJ: Purification and properties of heme-deficient hepatic soluble guanylate cyclase: Effects of heme and other factors on enzyme activation of NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys 1982;218:187-198.
32. Wolin MS, Wood KS, Ignarro LJ: Guanylate cyclase from bovine lung: A kinetic analysis of the regulation of the purified soluble enzyme by protoporphyrin IX, heme, and nitrosyl-heme. J Biol Chem 1982;257:13312-13320.
33. Ignarro LJ, Wood KS, Wolin MS: Regulation of purified soluble guanylate cyclase by porphyrins and metalloporphyrins: A unifying concept. Adv Cyclic Nucleotide Protein Phosphor Res 1984;17:267-274.
34. Ignarro LJ, Buga GM, Wood KS, et al: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
35. Ignarro LJ, Byrns RE, Buga GM, et al: Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987;61:866-879.
36. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release-accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
37. Ignarro LJ, Harbison RG, Wood KS, et al: Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: Stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986;237:893-900.
38. Ignarro LJ, Wood KS, Byrns RE: Pharmacological and biochemical properties of endothelium-derived relaxing factor (EDRF): Evidence that EDRF is closely related to nitric oxide (NO) radical. (Abstract) Circulation 1986;74:II-287.
39. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
40. Rubanyi GM, Vanhoutte PM: Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
41. Beckman JS, Beckman TW, Chen J, et al: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
42. Azuma H, Ishikawa M, Sekizaki S: Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986;88:411-415.
43. Ignarro LJ: Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
44. Ignarro LJ, Byrns RE, Wood KS: Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ Res 1987;60:82-92.
45. G-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989;160:881-886.
46. Rees DD, Palmer RM, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
47. G)-amino-L-arginine on EDRF function in the rat: Evidence for continuous basal EDRF release. J Pharmacol Exp Ther 1991;257:1208-1215.
48. Bevan JA, Joyce EH: Flow-dependent dilation in myograph-mounted resistance artery segments. Blood Vessels 1988;25:101-104.
49. Buga GM, Gold ME, Fukuto JM, et al: Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991;17:187-193.
50. Hintze TH, Vatner SF: Reactive dilation of large coronary arteries in conscious dogs. Circ Res 1984;54:50-57.
51. Holtz J, Giesler M, Bassenge E: Two dilatory mechanisms of antianginal drugs on epicardial coronary arteries in vivo: Indirect, flow-dependent, endothelium-mediated dilation and direct smooth muscle relaxation. Z Kardiol 1983;72:98-106.
52. Holtz J, Förstermann U, Pohl U: Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: Effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol 1984;6:1161-1169.
53. Hull SS, Kaiser L, Jaffe MD, et al: Endothelium-dependent flow-induced dilation of canine femoral and saphenous arteries. Blood Vessels 1986;23:183-198.
54. Kaiser L, Hull SS Jr, Sparks HV Jr: Methylene blue and ETYA block flow-dependent dilation in canine femoral artery. Am J Physiol 1986;250:H974-H981.
55. Rubanyi GM, Romero JC, Vanhoutte PM: Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H1145-H1149.
56. Tesfamariam B, Halpern W, Osol G: Effects of perfusion and endothelium on the reactivity of isolated resistance arteries. Blood Vessels 1985;22:301-305.
57. Ayajiki K, Kindermann M, Hecker M: Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ Res 1996;78:750-758.
58. Fleming I, Bauersachs J, Busse R: Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J Vasc Res 1997;34:165-174.
59. Rogers NE, Ignarro LJ: Constitutive nitric oxide synthase from cerebellum is reversibly inhibited by nitric oxide formed from L-arginine. Biochem Biophys Res Commun 1992;189:242-249.
60. Buga GM, Griscavage JM, Rogers NE, et al: Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 1993;73:808-812.
61. Cohen GA, Hobbs AJ, Fitch RM, et al: Nitric oxide regulates endothelium-dependent vasodilator responses in rabbit hindquarters vascular bed in vivo. Am J Physiol 1996;271:H133-H139.
62. Abu-Soud HM, Wang J, Rousseau DL, et al: Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J Biol Chem 1995;270:22997-23006.
63. Ignarro LJ, Bush PA, Buga GM, et al: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170:843-850.
64. Rajfer J, Aronson WJ, Bush PA, et al: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-94.
65. Trigo-Rocha F, Aronson WJ, Hohenfellner M. Nitric oxide and cGMP: Mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 1993;264:H419-H422.
66. Bush PA, Gonzalez NE, Ignarro LJ: Biosynthesis of nitric oxide and citrulline from L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum. Biochem Biophys Res Commun 1992;186:308-314.